3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Renal Cell
5
von Hippel-Lindau Disease
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Hemangioblastoma
1
Endometrial Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Interventions
Cyclophosphamide
9
Temozolomide
7
Radiotherapy
6
Magnetic Resonance Spectroscopy
5
Filgrastim
5
Cisplatin
5
Carboplatin
5
antineoplaston AS 2-1
4
antineoplaston A10
4
Etoposide
4
sargramostim
3
Vincristine
3
Thiotepa
3
Melphalan
3
Automobiles
3
fludarabine
2
aldesleukin
2
Thalidomide
2
Surveys and Questionnaires
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Gadolinium DTPA
2
Eflornithine
2
Donepezil
2
Carmustine
2
Biopsy
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
trifluridine tipiracil drug combination
1
trametinib
1
thymoglobulin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neuroectodermal Tumors, Primitive
×
belzutifan
×
Clear all
NCT07167329
2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2
Recruiting
100 enrolled